Loading quotes...
Forecast
| Buy |
Â
0 |
| Hold |
Â
0 |
| Sell |
Â
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2025 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -159.1 | - |
| EBITDA | 0 | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ5.5K |
Number of shares | 41.71K |
52-week high/low | âŹ0.17 - âŹ0.00 |
| Dividends | No |
Beta | 0.21 |
P/E ratio | 21.37 |
PEG ratio | 0.04 |
P/B ratio | 1.48 |
P/S ratio | 69.76 |
Company profile
Orphazyme A/S hat keine nennenswerte GeschĂ€ftstĂ€tigkeit. Zuvor war das Unternehmen in der Entwicklung von Therapien fĂŒr die Behandlung seltener neurodegenerativer Erkrankungen tĂ€tig. Das Unternehmen wurde im Jahr 2009 gegrĂŒndet und hat seinen Hauptsitz in Kopenhagen, DĂ€nemark.
| Name | Orphazyme Aktie |
| CEO | Jakob FĂŠrch Bendtsen |
| Headquarters | Copenhagen,
Denmark |
| Website | |
| IPO | 07/16/2019 |
| Employees | 1 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Copenhagen | ORPHA.CO |
Frankfurt | 1TB0.F |
London | 0CUM.L |
MĂŒnchen | 1TB0.MU |
DĂŒsseldorf | 1TB0.DU |